How do I find FDA warning letters for a compounding pharmacy?
How do I find FDA warning letters for a compounding pharmacy?
Search FDA’s warning letter database for the pharmacy’s legal name, any “dba” name and its city, then check FDA’s compounding inspections and actions page, which lists 111 warning letters to 105 compounding facilities along with Form 483s and close-out letters (current as of Oct 22, 2026). In this index, 9 GLP-1 warning letters went to compounding pharmacies or outsourcing facilities, the latest dated Sep 18, 2026 to Empower Clinic Services, LLC dba Empower Pharmacy.
Steps
- FDA’s warning letter database: search the legal name and the “dba” name separately. FDA’s subject line for compounders usually reads “Compounding Pharmacy/Adulterated Drug Products” or names CGMP.
- FDA’s compounding inspections and actions list: the pharmacy’s entry links each warning letter, close-out letter and Form 483 FDA has posted since 2019. FDA keeps earlier actions in an archive.
- Check for a close-out letter: it means FDA completed its review of the firm’s corrective actions.
Warning letters to compounders since 2025 on FDA’s actions list
| Letter | ||||
|---|---|---|---|---|
| Sep 18, 2026 | Empower Clinic Services, LLC, (dba Empower Pharmacy) | Houston, TX | 503A | fda.gov |
| Apr 7, 2026 | ProRX LLC | Exton, PA | 503B | fda.gov |
| Mar 20, 2026 | RC Outsourcing LLC | Lowellville, OH | 503B | fda.gov |
| Feb 9, 2026 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions | Englewood, CO | 503A | fda.gov |
| Feb 2, 2026 | Apollo Care LLC | Columbia, MO | 503B | fda.gov |
| Jan 20, 2026 | GenoGenix, LLC | Boca Raton, FL | 503B | fda.gov |
| Jan 16, 2026 | Boothwyn Pharmacy LLC | Kennett Square, PA | 503A | fda.gov |
| Dec 12, 2025 | MedisourceRx | Los Alamitos, CA | 503B | fda.gov |
| Dec 1, 2025 | Apothecary Pharma LLC | Cary, NC | 503B | fda.gov |
| Nov 7, 2025 | Wells Pharma of Houston LLC | Houston, TX | 503B | fda.gov |
| Oct 10, 2025 | PQ Pharmacy, LLC | Brooksville, FL | 503B | fda.gov |
| Sep 22, 2025 | Revive RX LLC, dba Revive RX Pharmacy | Houston, TX | 503A | fda.gov |
| Sep 16, 2025 | Turbare Manufacturing | Conway, AR | 503B | fda.gov |
| Jul 2, 2025 | Exela Pharma Sciences, LLC | Lenoir, NC | 503B | fda.gov |
| May 5, 2025 | Staska Pharmaceuticals, Inc. | Bennet, NE | 503B | fda.gov |
| Apr 23, 2025 | OSRX, Inc. | Missoula, MT | 503B | fda.gov |
| Apr 8, 2025 | Tailstorm Health, Inc. | Phoenix, AZ | 503B | fda.gov |
| Apr 2, 2025 | Empower Clinic Services, LLC, (dba Empower Pharmacy) | Houston, TX | 503B | FDA copy (archived) |
| Apr 2, 2025 | Empower Clinic Services, LLC, (dba Empower Pharmacy) | Houston, TX | 503A | fda.gov |
| Mar 5, 2025 | Annovex Pharma, Inc. | Lorton, VA | 503B | fda.gov |
| Mar 4, 2025 | ProRX LLC | Exton, PA | 503B | FDA copy (archived) |
| Jan 22, 2025 | Nubratori Inc. dba Nubratori Rx | Torrance, CA | 503B | FDA copy (archived) |
GLP-1 warning letters to compounding pharmacies and outsourcing facilities
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Sep 18, 2026 | Empower Clinic Services, LLC dba Empower Pharmacy | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 7, 2026 | ProRx LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 9, 2026 | Thrive Health and Wellness, LLC dba Thrive Health Solutions | Compounding Pharmacy/Adulterated Drug Products | Tirzepatide | Close-out letter, Aug 6, 2026 | fda.gov |
| Jan 20, 2026 | GenoGenix LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 16, 2026 | Boothwyn Pharmacy, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 1, 2025 | Apothecary Pharma, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Oct 10, 2025 | PQ Pharmacy, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 8, 2025 | Tailstorm Health Inc. dba Medivant Health | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | Close-out letter, Apr 14, 2026 | fda.gov |
| Mar 4, 2025 | ProRx, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Common questions
What is the difference between a warning letter and a Form 483?
A Form 483 lists conditions FDA investigators observed at the end of an inspection and is not a final agency determination. A warning letter is FDA’s formal notice of what it considers significant violations, and asks the firm to respond.
Where are warning letters older than 2019?
FDA’s compounding actions page links an archived version for actions before 2019, and the warning letter database itself can be searched by date range.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- FDA: Compounding: Inspections, Recalls, and other Actions
Records last pulled Nov 15, 2026. Every entry links to the original public record.